FDA gives Lilly’s Olumiant breakthrough status for hair loss

Incyte's JAK inhibitor for GVHD fails phase 3 trial

Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a company in need of more drug successes.

Gilead says arthritis drug filgotinib fails in follow-up use...

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum

AbbVie prices Rinvoq close to Humira after arthritis approva...